German Regulator Backs Veraxa's BiTAC-TCE Cancer Therapy Plan, De-Risking Path to Clinic
VRXA sits 31% above its 52-week low of $1.7.
Summary
Veraxa received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) supporting the biological rationale and proposed non-clinical development plan for its lead BiTAC-TCE program. This early regulatory alignment de-risks the path toward clinical trials for the novel dual-targeting T cell engager platform. The feedback follows promising in vitro and in vivo data presented at AACR 2026 showing a superior safety profile with matching efficacy versus traditional TCEs. For a $69M market cap biotech, regulatory endorsement of the development strategy is a material positive, reducing uncertainty around the program's advancement. The company had previously announced in vitro proof-of-concept for its BiTAC-ADC platform in June, but this is the first regulatory interaction for the TCE modality. Next steps include advancing toward IND-enabling studies, though no specific timeline was provided.
At the time of this announcement, VRXA was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $1.70 to $27.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.